An Innovative PDX and Patient-derived 3D Platform for Improved Translatability of New Medical Entities

Recent advances in the preclinical landscape revolutionized our approach to understanding cancer mechanisms and testing potential therapeutics.
Patient-derived 3D cultures provide a more faithful representation of pathophysiology compared to traditional 2D culture systems. However, the ability of these patient-derived models to predict clinical drug efficacy relies not only on experimental optimization but also on the retention of molecular and histological characteristics of the original tumor while offering higher throughput potential, and a quick turnaround time compared to in-vivo studies.

At Champions Oncology, we utilized our proprietary bank of more than 1500 patient-derived xenografts (PDXs) comprising ~50 different tumor indications to establish Champions TumorGraft3D (CTG3D) an innovative ex-vivo platform. Notably, this large cohort of clinically relevant and pre-treated TumorGraft models are well-characterized at the molecular and pharmacological levels.